- Trial phase
- Approved
- Time to market
- Already approved (2015) but discontinued in the US. Still available in some international markets.
- Why 2/10
- No hard, dated catalyst is scheduled for Ryzodeg in the next ~12 months. The drug was approved in 2015 and has been discontinued in the US market. It is a legacy product with no pending regulatory decisions, label expansions, or pivotal readouts. For Novo Nordisk (NVO), a DKK 309 billion revenue company driven by GLP-1 products like Ozempic and Wegovy, Ryzodeg is a negligible part of the pipeline.
Ryzodeg is a legacy product with no upcoming catalysts and has been discontinued in the US. For Novo Nordisk (NVO) investors, the drug is not a factor in the investment thesis. Watch NVO's Q3 2026 earnings and the ongoing competitive dynamics between Novo Nordisk's GLP-1 franchise (Ozempic, Wegovy) and Eli Lilly's incretin portfolio instead.
Price Chart
Executive Summary
Ryzodeg 70/30 is a pre-mixed insulin (70% insulin degludec + 30% insulin aspart) developed by Novo Nordisk. It was FDA-approved in September 2015 for diabetes management in adults and children 1 year and older. However, the product has been discontinued in the United States and is no longer commercially available there, with discontinuations also reported in Australia (February 2025). For Novo Nordisk, a DKK 309 billion revenue company whose growth is overwhelmingly driven by GLP-1 blockbusters (Ozempic, Wegovy), Ryzodeg is a legacy product with no material impact on the stock.
How It Works
Ryzodeg is a pre-mixed insulin shot that combines two types of insulin in one injection: 70% insulin degludec (an ultra-long-acting basal insulin that works slowly and lasts about 24 hours) and 30% insulin aspart (a rapid-acting mealtime insulin that works quickly after eating). This gives patients both background and mealtime blood sugar control in a single daily injection.
Trial Status
Ryzodeg was FDA-approved on September 25, 2015, after an initial Complete Response Letter in February 2013 that required a dedicated cardiovascular outcomes trial (DEVOTE). The resubmission included interim DEVOTE data showing cardiovascular safety. The drug is approved for adults and pediatric patients 1 year of age and older with type 1 or type 2 diabetes. However, the product has been discontinued in the US market and is no longer commercially available there.
The Two-Sided Case
Upcoming Catalysts
- No upcoming catalysts identified. Ryzodeg is a legacy approved product that has been discontinued in the US market.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report